NetworkNewsBreaks

FridayApr 29, 2022 1:16 pm

NetworkNewsBreaks – Vantage Hemp Company Announces Submission of DMF, Reinforces Commitment to Deliver Superior API Quality

Vantage Hemp has submitted a Drug Master File (“DMF”) to the U.S. Food & Drug Administration (“FDA”) covering its hemp-derived cannabidiol (“CBD”) distillate. According to the announcement, the submission further reinforces Vantage as a transparent, reliable and compliant partner, committed to working with pharmaceutical companies to formulate its CBD active pharmaceutical ingredient (“API”). The filing, which also strengthens Vantage’s position as an industry leader, represents the company’s commitment to support its clients through all phases of drug development. The company also noted that it anticipates filing future DMF submissions as it works to deliver superior API quality. “Our distillate DMF…

Continue Reading

FridayApr 29, 2022 11:12 am

NetworkNewsBreaks — Cepton Technologies Inc. (NASDAQ: CPTN) Schedules Release of Q1 2022 Financial Report, Conference Call

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance Micro Motion Technology(RM) (“MMT”) lidar solutions, announced that it anticipates releasing its 2022 first-quarter financial results on May 11, 2022; the company will also provide a business update at that time. The information will be released after market close. In addition, Cepton announced that it will hold a conference call and webcast that same day at 5 p.m. ET. Those interested in participating on the call can dial 844-826-3035 or watch the webcast live. Those unable to participate in the live event can listen to a reply of the…

Continue Reading

FridayApr 29, 2022 10:57 am

NetworkNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) to Participate in Luxury Meets Cannabis Conference

Flora Growth’s (NASDAQ: FLGC) executives Luis Merchan and James Choe are scheduled to participate at the upcoming Luxury Meets Cannabis Conference. The two-day event is scheduled for May 5–6, 2022, in New York City. The premier B2B CBD, hemp and cannabis event — the first of its kind — is an ideal venue to shine a spotlight on FLGC’s impressive line of lifestyle products and brands. The conference is designed to bring together premium CBD, hemp and cannabis brands and their founders with representatives from top mainstream retailers, global media, leading dispensaries and investors. Flora Growth is a leading all-outdoor cannabis cultivator…

Continue Reading

FridayApr 29, 2022 10:44 am

NetworkNewsBreaks – Arogo Capital Acquisition Corporation (NASDAQ: AOGOU) Enters Agreement with AR/VR, Knowledge Metaverse Company

Arogo Capital Acquisition (NASDAQ: AOGOU), a special purpose acquisition corporation (“SPAC”), has entered into a definitive business combination agreement with EON Reality Inc. With its two decades of experience, EON has built a reputation for being a leader in virtual and augmented reality (“ARVR”) along with knowledge Metaverse industry and education solutions. According to the agreement, the two companies will combine to become a public company named EON Reality Inc., which will be listed on the Nasdaq market exchange. The announcement noted that EON Reality chair and CEO Dan Lejerskar will maintain his position as head of the combined company.…

Continue Reading

ThursdayApr 28, 2022 3:17 pm

NetworkNewsBreaks – Nowigence Inc. Streamlining How Teams Use Intelligence to Make Decisions, Complete Tasks

Nowigence provides a unique solution to the growing challenge of collaboration overload and the desperate need for tools that identify, organize and distribute information in a uniform way to provide access to critical information. The company accomplishes this through its Pluaris offering, which reads and analyzes articles, documents and other textual data, enabling users to learn more in less time, uncover hidden insights, and stay on top of the information they need to know. A recent article, which contains excerpts from Nowigence’s website, reads: “‘Communication is hard, and information is easily lost in translation, leading to duplication of effort in…

Continue Reading

ThursdayApr 28, 2022 3:03 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its applied research and development (“R&D”) programs. “So far, the company’s research journey has involved a series of controlled and well-designed in vitro preclinical testing and in vivo animal and human clinical studies…. Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research.…

Continue Reading

ThursdayApr 28, 2022 2:42 pm

NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions in a commitment to transform the mental health treatment landscape. Through its proprietary deuterated process, Cybin is combining controllable drug-delivery systems with novel psychedelic molecules, thus creating patent-protected, commercially scalable drug candidates. “The company currently is moving three of these drug candidates forward: CYB003, CYB004 and CYB005. Cybin’s active drug programs target major depressive disorder (CYB003), alcohol use disorder (CYB003), anxiety disorders (CYB004) and neuroinflammation (CYB005),” reads a recent article. “Cybin recently announced that it commenced a…

Continue Reading

ThursdayApr 28, 2022 1:49 pm

NetworkNewsBreaks – NetworkNewsWire to Serve as Official NewsWire for Full Slate of Finovate 2022 Events

IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands, today announced that its NetworkNewsWire brand was designated as the official newswire for conferences hosted by Finovate for another full year. IBN will continue to serve as the corporate communications firm for Finovate events. A research and events firm focused on innovation in financial and banking technology, Finovate hosts a full lineup of events, including FinovateEurope, FinovateSpring, FinovateFall, FinovateAwards and FinovateFocus, with content delivered via in-person and virtual formats. Well known for drawing high-level executives and fintech innovators, Finovate conferences feature expert speakers and presenters who offer…

Continue Reading

ThursdayApr 28, 2022 1:45 pm

NetworkNewsBreaks – SPYR Inc. (SPYR) Evaluating Potential IP Acquisitions, Product Line Additions

SPYR (OTCQB: SPYR), dba SPYR Technologies, a technology company, and its subsidiary, Applied Magix Inc., is exploring potential acquisition opportunities that would expand the company’s essential intellectual property (“IP”) or product lines. Applied Magix develops and resells Apple(R) ecosystem-compatible products in the growing multibillion-dollar smart home and connected car markets, is investigating possible acquisition targets to add essential intellectual property to its line of products, as well as new product lines. According to Applied Magix CEO Dr. Harald Zink, Applied Magix is always on the lookout for new and innovative technologies and has recently identified several potential IP targets that are AI-based and…

Continue Reading

ThursdayApr 28, 2022 1:36 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced its receipt of approval from the Spanish Agency for Medicines and Health Products (“AEMPS”) Competent Authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for CNSP’s potentially pivotal study of Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. “We continue to build momentum in our potentially pivotal study of Berubicin, and importantly advance toward bringing…

Continue Reading